人类白细胞抗原基因型对接受初始雄激素剥夺治疗的晚期前列腺癌生存的影响:KYUCOG-1401-A研究
KYUCOG-1401-A是一项前瞻性研究,纳入127例接受初始雄激素剥夺治疗的日本晚期前列腺癌患者,检测HLA-A、B、C、DRB1、DQB1和DPB1基因型。结果显示HLA-DRB1和HLA-DQB1纯合与前列腺癌特异性死亡风险升高相关,而HLA-DQB1进化分歧评分较高与风险降低相关。研究提示HLA-II类基因多样性在晚期前列腺癌生存中起重要作用。
要点
- HLA-DRB1纯合与前列腺癌特异性死亡风险升高相关(HR 4.05)。
- HLA-DQB1纯合与前列腺癌特异性死亡风险升高相关(HR 3.75)。
- HLA-DQB1进化分歧评分较高与前列腺癌特异性死亡风险降低相关(HR 0.90)。
核心结论
- 研究提示包括HLA-DRB1和HLA-DQB1在内的HLA-II类位点多样性在晚期前列腺癌生存中起重要作用,有助于改善晚期前列腺癌的风险分层。
- 研究显示CD4+ T细胞在雄激素剥夺治疗中起重要作用,提示靶向CD4+ T细胞的免疫治疗对前列腺癌有前景。
研究设计与样本
- KYUCOG-1401-A是与前瞻性临床试验KYUCOG-1401联合开展的研究,仅纳入KYUCOG-1401中接受初始雄激素剥夺治疗的日本患者,共127例。
- 检测HLA-A、B、C、DRB1、DQB1和DPB1基因型,评估HLA基因型分歧对至进展时间、前列腺癌特异性生存和总生存的影响。
主要发现
- 在127例患者中,HLA-DRB1纯合与前列腺癌特异性死亡风险升高相关(HR 4.05,95%CI 1.54-10.7,P=0.0047)。
- HLA-DQB1纯合与前列腺癌特异性死亡风险升高相关(HR 3.75,95%CI 1.47-9.58,P=0.0058)。
- HLA-DQB1进化分歧评分较高的患者前列腺癌特异性死亡风险较低(HR 0.90,95%CI 0.82-0.97,P=0.0093)。
- 在前列腺癌队列中,CD4low和CD8low肿瘤的雄激素反应基因集上调,但在膀胱癌和肾癌队列中未上调。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune editing, in which human leukocyte antigens (HLA) have critical roles, has been suggested to shape the landscape of human cancer. This study prospectively investigated whether HLA gene zygosity is associated with the prognosis of primary androgen deprivation therapy in advanced prostate cancer. METHODS: KYUCOG-1401-A was conducted in conjunction with a prospective clinical trial (KYUCOG-1401). Among the patients enrolled in KYUCOG-1401 and treated with primary androgen deprivation therapy, only Japanese patients were included. HLA genotypes of HLA-A, B, C, DRB1, DQB1, and DPB1 were determined. The effect of divergence of HLA genotypes on time to progression, prostate cancer-specific survival, and overall survival was evaluated. RESULTS: Among 127 patients, homozygosity for HLA-DRB1 (HR, 95% CI; 4.05, 1.54-10.7, P = 0.0047) and HLA-DQB1 (HR, 95% CI; 3.75, 1.47-9.58, P = 0.0058) was associated with an increased risk of prostate cancer-specific mortality. Patients with higher HLA evolutionary divergence scores at HLA-DQB1 (HR, 95% CI; 0.90, 0.82-0.97, P = 0.0093) had lower risks of prostate cancer-specific mortality. Androgen-responsive gene sets were upregulated in CD4low and CD8low tumors in the prostate cancer cohort, but not in the bladder and kidney cancer cohorts. CONCLUSIONS: This study suggested that the diversity of HLA-II loci including HLA-DRB1 and HLA-DQB1 plays an important role in advanced prostate cancer survival, contributing to improved risk stratification in advanced prostate cancer. Moreover, it was shown that CD4+ T cells play an important role in androgen deprivation therapy, suggesting that immunotherapy targeting CD4+ T cells is promising for prostate cancer.
引用
- Shiota M, Tanegashima T, Tatarano S, et al. The effect of human leukocyte antigen genotype on survival in advanced prostate cancer treated with primary androgen deprivation therapy: the KYUCOG-1401-A study. Prostate Cancer Prostatic Dis. 2024. PMID: 38368501. doi:10.1038/s41391-024-00808-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。